Drug intelligence / Profile preview

WRG-28

Development stage: Preclinical
Lead developer: Washington University in St. Louis
Modality: Small Molecules
Administration: Intravenous

Overview

WRG-28 is a potent and selective, allosteric small molecule inhibitor of discoidin domain receptor 2 (DDR2). It acts extracellularly to inhibit receptor–ligand interactions via allosteric modulation, primarily blocking the collagen-induced activation of DDR2. By targeting DDR2, WRG-28 inhibits tumor cell invasion and migration, suppresses tumor-supporting stromal interactions, and reduces metastatic colonization in models of metastatic breast cancer. Preclinical data also suggest efficacy in rheumatoid arthritis models[1][2][3][5][7][9].

Targets

DDR2 (Discoidin domain receptor tyrosine kinase 2)

Beyond the preview

Go deeper on WRG-28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WRG-28.

Explore the full profile